In a clinicopathological analysis of 156 ovarian cancer patients, Aurora B expression was significantly higher in poor and moderately differentiated ovarian cancers (53.6% and 28.2% with high expression) than in well-differentiated cancers (10.0% with high expression) (P = 0.02). Here, AURKB is linked to ovarian cancer.